Sirnaomics’ siRNA Therapeutic To Begin Clinical Trials In China
This article was originally published in PharmAsia News
SHANGHAI - Sirnaomics' RNAi therapeutic STP601 will begin clinical trials in China in late 2008, Patrick Lu, founder, president and CEO of Sirnaomics, told PharmAsia News
You may also be interested in...
Chinese small interfering siRNA supplier Shangahi GenePharma has acquired a nonexclusive worldwide license to Alnylam Pharmaceuticals' Kreutzer-Limmer patent group, which is the first business transaction in China made by the Cambridge, Mass.-based RNAi firm
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.